الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 97 |  |  |
| | | from | 97 | | |
Abstract
Immune thrombocytopenia (ITP) is one of the most common acquired bleeding disorders of childhood and is defined as an autoimmune disorder characterized by isolated thrombocytopenia in the absence of other causes or disorders associated with thrombocytopenia. ITP can often elicit other autoimmune disorders
The aim of our study was to determine the prevalence of anti-thyroid (Anti-TPO and Anti-Tg) antibodies and anti-cardiolipin (Anti-CL) antibodies in children with immune thrombocytopenia and their clinical significance.
The present study was carried out on 60 children who already diagnosed as primary immune thrombocytopenia children (ITP group), they were grouped into 2 groups:
• group 1 (newly diagnosed and persistent ITP): included 30 children with ITP for less than 1 year. They were 16 males and 14 females, their ages ranged from 8 months to13 years.
• group 2 (chronic ITP): included 30 patients with ITP for more than 1 year. They were 22 males and 8 females, their ages ranged from 2 to 14 years.
The study also included 25 apparently healthy children, matched with age and sex with ITP group, who served as a control group. They were 16 males and 9 females, their ages ranged from 1 to 14 years.
The study revealed that Anti-TPO, Anti-Tg and Anti-CL were significantly higher in ITP children than the control; ATA and Anti-CL were significantly more positive in the ITP children than the control. There was a significant negative correlation between Anti-TPO and platelet count.
For a child to be older and with older age at onset of the disease had significantly higher odd ratio for predicting positive Anti-CL.
Although there were differences in the antibodies level between infantile and pediatric ITP cases and between children who received cytotoxic therapy and those did not receive cytotoxic therapy, these changes were not of statistical significance.
from this we can conclude that ITP children may have other antibodies rather than antiplatelets antibodies, this may be a concealed presentation of other autoimmune diseases which may appear many years after diagnosis of ITP.